Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 18/20 | 0.52 |
| ▸ | HTR1A | P08908 | 8/20 | 0.50 |
| ▸ | DRD2 | P14416 | 4/20 | 0.49 |
| ▸ | DRD5 | P21918 | 3/20 | 0.49 |
| ▸ | DRD3 | P35462 | 3/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4945212 | 0.84 | HTR7 (0.52) | HTR7HTR1ADRD2DRD5DRD3 | |
| SCHEMBL8240109 | 0.80 | HTR7 (0.57) | HTR7HTR1ADRD2DRD5DRD3 | |
| SCHEMBL7476444 | 0.78 | DRD2 (0.63) | HTR7HTR1ADRD2DRD5DRD3 | |
| SCHEMBL1232169 | 0.77 | HTR7 (0.57) | HTR7HTR1ADRD2DRD5DRD3 | |
| SCHEMBL3227442 | 0.77 | HTR7 (0.57) | HTR7HTR1ADRD2DRD5DRD3 | |
| SCHEMBL6696116 | 0.77 | HTR7 (0.57) | HTR7HTR1ADRD2DRD5DRD3 | |
| SCHEMBL5999408 | 0.77 | HTR7 (0.57) | HTR7HTR1ADRD2DRD5DRD3 | |
| SCHEMBL318502 | 0.77 | HTR7 (0.57) | HTR7HTR1ADRD2DRD5DRD3 | |
| SCHEMBL29612136 | 0.77 | HTR7 (0.57) | HTR7HTR1ADRD2DRD5DRD3 | |
| SCHEMBL4656369 | 0.77 | HTR7 (0.57) | HTR7HTR1ADRD2DRD5DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1866277-B1 | SULFONYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | VIROBAY INC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-20080287446-A1 | Sulfonyl Containing Compounds as Cysteine Protease Inhibitors | QUEST DIAGNOSTICS INVESTMENTS LLC | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287446-A1 | Sulfonyl Containing Compounds as Cysteine Protease Inhibitors | CTSS, CTSF, CTSB | HTR7 3655/4885HTR1A 4268/4885DRD2 4430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.